Every 10-Q that Inhibrx Biosciences, Inc. (INBX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INBX filings page.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing the DR5 agonist ozekibart (INBRX-109) and the OX40 agonist INBRX-106. Cash and cash equivalents were $133.3 million as of June 30 2026, with an accumulated deficit of $316.3 million and a stockholders’ equity deficit of $53.0 million.
For the six months ended June 30 2026, the company generated no revenue versus $1.3 million a year earlier, incurred research and development expenses of $49.1 million (down 17%), general and administrative expenses of $14.0 million (up 12%), and reported a net loss of $70.1 million. Long‑term debt under the Oxford facility totaled $176.3 million, with an effective interest rate of 17.5%, and a subsequent amendment in July 2026 added up to $325.0 million of additional borrowing capacity, including $100.0 million already drawn.
Clinically, ozekibart showed a statistically significant progression‑free survival benefit in a registrational chondrosarcoma trial, and a biologics license application was accepted by the FDA in June 2026. Interim data in colorectal cancer and Ewing sarcoma, and positive Phase 2 HexAgon data for INBRX‑106 in head and neck cancer, support further late‑stage development.
Inhibrx Biosciences reported a Q1 2026 net loss of $33.4M, narrowing from $43.3M a year earlier as operating expenses fell. Research and development dropped 32% to $25.2M, mainly from lower chondrosarcoma trial and manufacturing costs, while general and administrative expense was $5.7M.
Cash and cash equivalents were $161.7M as of March 31, 2026, and management believes this will fund operations for at least 12 months, but long‑term debt rose to $175.0M after drawing an additional $75.0M term loan at an effective interest rate of 17.5%.
The pipeline advanced meaningfully. Ozekibart showed encouraging efficacy in colorectal cancer and Ewing sarcoma and has a biologics license application filed for conventional chondrosarcoma after a registrational trial more than doubled median progression‑free survival to 5.52 months. INBRX‑106 delivered higher response rates than pembrolizumab alone in first‑line head and neck cancer, with a Phase 3 HexAgon study planned to start in the third quarter of 2026.
Inhibrx Biosciences (INBX) filed its Q3 2025 report, showing steady cash and ongoing investment in its pipeline. Cash and cash equivalents were $153.1 million as of September 30, 2025, with management stating this should fund operations for at least 12 months. The company reported a net loss of $35.3 million for the quarter and $107.2 million year to date. Year‑to‑date revenue was $1.3 million from a Scithera license.
Operating expenses decreased versus the prior year period, with research and development at $87.7 million year to date (vs. $170.4 million in 2024) and general and administrative at $17.7 million (vs. $111.2 million in 2024, which included merger-related items). Long‑term debt was $99.9 million, reflecting the $100.0 million term loan entered on January 13, 2025; interest expense was $9.0 million year to date.
The pipeline advanced: ozekibart (INBRX‑109) met its Phase 2 primary endpoint in chondrosarcoma, more than doubling median PFS to 5.52 months versus 2.66 months for placebo (hazard ratio 0.479; P<0.0001). Shares outstanding were 14,498,093 as of September 30, 2025.
Inhibrx Biosciences reported a materially different quarter versus the prior-year period driven by the post‑spin financial position and new financing. Revenue was $1.3 million for the quarter from a Scithera license, while operating expenses were $28.7 million leading to an operating loss of $27.4 million and a net loss of $28.654 million for the three months ended June 30, 2025. The prior-year period included a $2.02 billion gain related to the Merger with the Former Parent, which produced the large net income figure in 2024.
The balance sheet shows $186.6 million cash and equivalents and total assets of $212.1 million, with accumulated deficit of $178.1 million. The company established long-term debt under a 2025 Loan Agreement with Oxford resulting in long-term debt, net of discount, of $99.3 million. Management states existing cash is sufficient to fund operations for at least 12 months. Clinically, the company continues development of ozekibart (INBRX-109) and INBRX-106, and completed full enrollment in its registration‑enabling chondrosarcoma trial in July 2025.